If you have any questions about clinical research at East Florida Eye Institute, or are interested in participating in a clinical trial, please contact us using this form

You may also submit your contact information and diagnosis if you would like to be contacted for a future clinical trial.


Geographic Atrophy secondary to AMD

A TRIAL IS AVAILABLE FOR ANYONE OVER THE AGE OF 60 TO ASSES EFFICACY AND SAFETY OF INTRAVITREOUS ADMINISTRATION OF APL-2 THERAPY FOR GEOGRAPHIC ATROPHY. TOTAL STUDY DURATION IS 30 MONTHS

Wet AMD

1/3

A TRIAL IS AVAILABLE FOR ANYONE OVER THE AGE OF 50. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE SAFETY AND DURATION OF THE EFFECT OF LONG ACTING SUNITINIB MALATE (GB-102)INTRAVITREAL INJECTION COMPARED TO AFLIBERCEPT IN PATIENTS WITH WET AMD. TOTAL STUDY DURATION IS 12 MONTHS

Wet AMD

2/3

A TRIAL IS AVAILABLE FOR ANYONE OVER THE AGE OF 50. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE SAFETY AND EFFICACY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN A TREAT TO CONTROL REGIMEN IN TREATMENT NAÏVE PATIENTS, IN PATIENTS WITH WET AMD. TOTAL STUDY DURATION IS 64 WEEKS

Name *
Name

Blepharitis

A TRIAL IS AVAILABLE FOR ANYONE OVER THE AGE OF 50. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE SAFETY AND EFFICACY OF ISV-305 (0.1% DEXAMETHASONE) TO VEHICLE FOR BLEPHARITIS. TOTAL STUDY DURATION IS 30 DAYS.

Diabetic Macular Edema

A TRIAL IS AVAILABLE FOR ADULTS WHO HAVE VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA. THE PURPOSE OF THIS STUDY IS TO ASSESS THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT EVERY 4 WEEKS. TOTAL DURATION 12 MONTHS.

Wet AMD

3/3

A TRIAL IS AVAILABLE FOR ANYONE OVER THE AGE OF 50 THAT HAS SUBFOVEAL CNV LESIONS SECONDARY TO AMD. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE SAFETY AND EFFICACY OF BROLUCIZUMAB VERSUS AFLIBERCEPT EVERY 4 WEEKS FOR PERSISTENT RETINAL FLUID IN PATIENTS WITH WET AMD. TOTAL STUDY DURATION IS 52 WEEKS


Studies on the horizon:

biosimilar medication for amd • mebomian gland • biosimilar medication for dme


Special thanks to those who have participated in prior studies.

For those of you who have recently participated, thank you for helping us with recent approvals of:

eylea for wet macular degeneration and crvo • lucentis and OZURDEX for diabetic macular edema • omidria for cataract surgery • zioptan and simbrinza for glaucoma